Recent Finacing
Recent Raise
Seneca Therapeutics is a clinical-stage biopharma developing SVV-001, a TEM8-targeting oncolytic virus and armed derivatives, conducting Phase I/II combination trials with checkpoint inhibitors and a companion diagnostic.
